Biology subjects

Marion, E.

Publications and source records attributed to Marion, E..

3 recordsLinked to original sources

bioRxiv2023

Overexpression of an apple broad range agglutinating lectin does not promote in planta resistance to fire blight and bacterial wilt.

Lectins, a large group of proteins present in all kingdoms of life can bind reversibly to glycans. The roles of plant lectins are diverse and include resistance to biotic or abiotic stress, notably bacterial resistance. A gene family encoding amaranthin-like lectins termed MdAGGs in apple (Malus domestica) has been identified to be overexpressed upon treatment with the plant resistance inducer acibenzolar-S-methyl (ASM) which promotes enhanced resistance to the fire blight disease caused by Erwinia amylovora (Ea). In this study, we first screened the ability of purified MdAGG10 to agglutinate bacterial cells in vitro among a range of bacterial species. Several bacterial species, either Gram positive or negative, either plant- or human-pathogens were found to be agglutinated by MdAGG10 in acidic conditions. Apple and Arabidopsis lines constitutively overexpressing MdAGG10 were generated and evaluated for their resistance to, respectively, Ea and Ralstonia solanacearum, both plant pathogens that were found in our screening. Despite MdAGG10 protein accumulated in tissues of both apple and Arabidopsis lines, they remained susceptible to their respective pathogens. Interestingly, in vitro agglutination of Ea by MdAGG10 did not impair bacterial growth, suggesting that other plant molecules are involved in the resistance to fire blight triggered after an ASM treatment.

plant biology↗

bioRxiv2020

High antibody titres induced by protein subunit vaccines against Buruli ulcer using Mycobacterium ulcerans antigens Hsp18 and MUL_3720

BackgroundMycobacterium ulcerans is the causative agent of a debilitating skin and soft tissue infection known as Buruli ulcer (BU). There is no vaccine against BU. The purpose of this study was to investigate the vaccine potential of two previously described immunogenic M. ulcerans proteins, MUL_3720 and Hsp18, using a mouse tail infection model of BU. MethodsRecombinant versions of the two proteins were each electrostatically coupled with a previously described lipopeptide adjuvant. Seven C57BL/6 and seven BALB/c mice were vaccinated and boosted with each of the formulations. Vaccinated mice were then challenged with M. ulcerans via subcutaneous tail inoculation. Vaccine performance was assessed by time-to-ulceration compared to unvaccinated mice. ResultsThe MUL_3720 and Hsp18 vaccines induced high titres of antigen-specific antibodies that were predominately subtype IgG1. However, all mice developed ulcers by day-40 post-M. ulcerans challenge. No significant difference was observed in the time-to-onset of ulceration between the experimental vaccine groups and unvaccinated animals. ConclusionsThese data align with previous vaccine experiments using Hsp18 and MUL_3720 that indicated these proteins may not be appropriate vaccine antigens. This work highlights the need to explore alternative vaccine targets and different approaches to understand the role antibodies might play in controlling BU.

microbiology↗

bioRxiv2019

Vaccine-specific immune responses against Mycobacterium ulcerans infection in a low-dose murine challenge model

The neglected tropical disease Buruli ulcer (BU) is an infection of subcutaneous tissue with Mycobacterium ulcerans. There is no effective BU vaccine. Here, we assessed an experimental prime-boost vaccine in a low-dose murine tail infection model. We used the enoyl-reductase (ER) domain of the M. ulcerans mycolactone polyketide synthases electrostatically coupled with a previously described TLR-2 agonist-based lipopeptide adjuvant, R4Pam2Cys. Mice were vaccinated and then challenged via tail inoculation with 14-20 colony forming units (CFU) of an engineered bioluminescent strain of M. ulcerans. Mice receiving either the experimental ER vaccine or Mycobacterium bovis Bacille Calmette-Guerin (BCG) were equally well protected, with both groups faring significantly better than non-vaccinated animals (p<0.05). A suite of 29 immune parameters were assessed in the mice at the end of the experimental period. Multivariate statistical approaches were then used to interrogate the immune response data to develop disease-prognostic models. High levels of IL-2 and low IFN-{gamma} produced in the spleen best predicted control of infection across all vaccine groups. Univariate logistic regression then revealed vaccine-specific profiles of protection. High titres of ER-specific IgG serum antibodies together with IL-2 and IL-4 in the draining lymph node (DLN) were associated with protection induced by the experimental ER vaccine. In contrast, high titres of IL-6, TNF-, IFN-{gamma} and IL-10 in the DLN and low IFN{gamma} titres in the spleen were associated with protection following BCG vaccination. This study suggests an effective BU vaccine must induce localized, tissue-specific immune profiles with controlled inflammatory responses at the site of infection.

immunology↗